Dr. Brad Reinfeld, MD PhD

@DrSamuelBHume Not too surprised Cat is out of the bag by the time patients show cognitive decline. Need to have better control of vascular risk factors for years prior to AD development….

Trials of oral semaglutide in early-stage symptomatic Alzheimer’s just published Two big, well-designed trials, and unfortunately, absolutely no effect:

@GIMedOnc @OncBrothers @MyriamChalabi @FASinicropeMD @BijoyTelivala @CathyEngMD @GIcancerDoc @manjuggm @dr_yakupergun @pashtoonkasi @AndreaCercek I think non-op could be used with very close monitoring. I sense AC could go that way. Have to take many patient factors. High risk for over treatment with surgery. I don’t know if we have great data to inform decision. Not so common situation.

@OncBrothers @MyriamChalabi @FASinicropeMD @BijoyTelivala @CathyEngMD @GIcancerDoc @manjuggm @dr_yakupergun @pashtoonkasi Is there a non-surgical option? I swear I’ve read something about non-operative management @AndreaCercek

For dMMR colon cancer, clinical Stage II (cT3-4N0 by imaging) do you rely on Ipi-Nivo upfront (NICHE-2) or Adj treatment (if upstaged per ATOMIC)? #gism @MyriamChalabi @FASinicropeMD @BijoyTelivala @CathyEngMD @GIcancerDoc @manjuggm @dr_yakupergun @GIMedOnc @pashtoonkasi

@DelgoffeLab pubmed.ncbi.nlm.nih.gov/12684396/ Believe it or not there is an approval. @WeillCornell’s Jedd Wolchokk has a liscensed K9 OV for mucosal melanoma. If I recall, @PatrickHwuMD had a pup who benefitted from this therapy!

@BReinfeld While that video is terrifying I’m glad to know ICI is becoming more widely deployed for the puppers. I think OVs would also be a stellar therapy. Regardless the story going around is just hyped bs from the techbro ai crowd.

Oh. The dog also got checkpoint blockade.

TET2-mutant clonal hematopoiesis prevents T-cell exhaustion and suppresses cancer metastasis biorxiv.org/content/10.648… #biorxiv_immuno

Congratulations to @LeoraBoussi of @MSKCancerCenter on winning the Ruben Mesa,MD Clinical Research Award & @Ruwan_Gunaratne of @Stanford on winning the Ronald Hoffman, MD Translational Research Award @ 4th Myeloid Malignancy @mpn_consortium and #MSSM @TheElfLab

Data establish glutamine synthetase (GS) as a key regulator of CD8+ T cells’ stress resilience in the tumor microenvironment, and GS inhibition offered a promising therapeutic strategy to enhance immune-based cancer treatments. Read this #EditorsChoice: ow.ly/tj3q50Yn65s.

🎉 Congratulations to MSK physician-scientist @KarunaMDPhD and colleagues, who are part of an international team awarded a @CancerGrand grant — a prestigious global award providing up to $25M over five years to tackle some of the toughest challenges in #cancerresearch. The team will explore new ways to “rewire” cancer cells and prevent treatment resistance in #colorectalcancer, one of the leading causes of cancer-related deaths. Learn more: bit.ly/4d1GX4p

What keeps a cancer center director up at night? Uncertainty in cancer research funding—and protecting the next generation of scientists. Kelvin Lee, MD, shares why resilience, advocacy and clinical trials matter now more than ever. Listen here: ow.ly/gElv50Yo7Tm.

Hey look! @nejm moved my writing to a new spot. Here's the first post, a rant about a particularly annoying requirement for those of us in work in hospitals (link below) 1/3

A True and Present Danger to US science 👇🏼

Congratulations to MSK's Dr. Andrea Cercek and Dr. Luis Diaz for being accepted into Round 1 of @statnews #STATMadness. Vote for their team now: bit.ly/3FfcuRu

Now online in @CD_AACR: A Tumor-Promoting Inflammatory SPP1+ Macrophage—IL-6—CRP Axis Drives Immune Dysfunction in Bladder Cancer - by @michelle_a_tran, Byuri Angela Cho, @sudeh9, Seong-Keun Yoo, @diegochowell, Matthew Galsky, @BhardwajLab, & colleagues @TischCancer @SinaiImmunol

Did you ever wonder why CRP was associated with poor outcomes in #BladderCancer ? So did we. pubmed.ncbi.nlm.nih.gov/41747249/ #GU26 @TischCancer @apolo_andrea @shilpaonc @BourlonMaite @PGrivasMDPhD @DrKarineTawagi @drenriquegrande @PGrivasMDPhD @urotoday @Uromigos @OncBrothers @OncoAlert

🧵 How do older patients actually do with dual IO for mccRCC? Presenting at #ASCOGU2026 a joint @MSKCancerCenter + @MDAndersonNews collaboration–the largest reported real-world cohort of patients treated with 1L ipilimumab/nivolumab (>500 pts). Here's what we learned ⬇️

At @ASCO #GU26, @motzermd presented phase 3 trial results showing that belzutifan + lenvatinib achieved superior PFS and ORR compared with cabozantinib in people with advanced #kidneycancer who progressed after immunotherapy. @MSKCancerCenter #RCC 🔗 bit.ly/4r4AYPD

@fabermdphd What about in the setting of orthopedic injuries?!?

Is CAR-T the future for the treatment of refractory debilitating rheumatological disease? I think so We'll see if the lower toxicity in this population (no ICANS, lower grade CRS) persists with larger studies nature.com/articles/s4159…

Age-related chromatin remodeling includes shared and specific signatures across cell types, sex, and organs science.org/doi/10.1126/sc… science.org/doi/10.1126/sc… @ScienceMagazine @junyue_cao @RockefellerUniv @ziyu__lu

Online now: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer dlvr.it/TR7k93

Myeloid core of TB granulomas is partitioned into two distinct metabolic environments, one of which is hypoxic & associated with pathological immune cell states that subvert immunity to TB @NatImmunol @Stanford @NIAIDNews @MikeAngeloLab nature.com/articles/s4159…